Novo Nordisk has resolved its patent infringement lawsuit against telehealth provider Hims & Hers, entering into a collaboration to distribute Novo Nordisk’s weight loss medications through the Hims ...

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss ...

Earnings date set: Hims & Hers will release Q1 2026 results on May 11, with consensus revenue near $616M and EPS at $0.13. Novo Nordisk pact: A March settlement allows sales of brand-name GLP-1 drugs, ...

Online health and wellness company Hims & Hers posted a $92 million loss in the first quarter as it transitions its weight loss business to selling branded GLP-1 weight loss treatments, shifting away ...

Novo Nordisk faces missed guidance as FDA limits on compounded GLP-1s shift the market, while HIMS diversifies offerings.

Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors pile into the stock ahead of a May 11 earnings report. The move caps a ...

Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement. JPMorgan analyst Cory Carpenter initiated coverage with an Overweight rating and a $35 price target, framing the telehealth ...